HGH Fragment 176-191: Fat Loss Evidence and Safety

HGH Fragment 176-191 is a synthetic peptide that copies the last stretch of the human growth hormone molecule, specifically amino acids 176 to 191 at its C-terminal end. Researchers isolated this section because the lipolytic, or fat-mobilising, activity of growth hormone appears to live in that tail, an idea that traces back to observations about growth hormone and fat metabolism in the late 1950s.

The appeal is the same as for any growth hormone fragment: the full hormone burns fat but also drives insulin resistance and broad growth effects, so a fragment that keeps the fat-burning part without the rest would, in theory, be a cleaner tool. The fragment is sold on that promise. What buyers are rarely told is that this raw sequence is the starting material, not the finished product.

The crucial distinction from AOD-9604

HGH Fragment 176-191 and AOD-9604 are routinely sold as interchangeable, and they are not the same molecule. AOD-9604 is an engineered version of this fragment: it adds a tyrosine residue and a disulfide bond to improve stability and bioactivity. The unmodified fragment is the original, less stable parent. That difference matters enormously, because every human clinical trial, roughly six studies in about 900 participants, was run on AOD-9604, not on the plain fragment. When a vendor cites “clinical safety” for HGH Fragment 176-191, they are almost always borrowing the record of a different molecule.

The bottom line: HGH Fragment 176-191 is the unmodified growth hormone tail, and conflating it with the more developed AOD-9604 overstates how much is actually known about it.

In animal models, HGH Fragment 176-191 is proposed to stimulate lipolysis and inhibit lipogenesis, in other words to encourage the breakdown of stored fat while discouraging the storage of new fat. It is described as not competing for the growth hormone receptor, which is the theoretical basis for the claim that it burns fat without growth hormone’s wider hormonal footprint. The lipolytic action is thought to run through the beta-3 adrenergic receptor pathway, the same mechanism characterised in detail in studies on the stabilised version covered in our AOD-9604 guide.

There is one mechanistic wrinkle that sets the unmodified fragment apart. Early work on synthetic C-terminal fragments of human growth hormone documented a hyperglycaemic action, and the raw sequence has been linked to insulin restriction. Part of the reason the molecule was modified at all was to refine this behaviour. So the common marketing line that the fragment has “no effect on blood sugar” is borrowed from the modified compound’s data and does not necessarily describe the parent. This is the single most under-reported caveat on vendor pages and the one most worth knowing.

The bottom line: the fragment’s proposed fat-burning mechanism mirrors its modified cousin’s, but its effect on blood sugar is less reassuring than the sales copy suggests.

There are no completed human efficacy trials of the unmodified HGH Fragment 176-191. This is the central fact of its evidence base, and it is the opposite of what most product pages imply.

Animal evidence

The fragment’s reputation rests on rodent studies. In obese mice, growth-hormone fragments in this family reduced body weight and fat mass, with some studies reporting roughly a 50 percent reduction in weight gain over about three weeks. The effect appears tied to the beta-3 adrenergic receptor, since genetically modified mice lacking that receptor do not respond. A telling nuance is that the rodent data track with body weight, working in obese animals but not in lean ones, which hints at a built-in regulatory ceiling rather than unlimited fat loss.

Human evidence

The human evidence that exists is for AOD-9604, the modified analogue, and it is not encouraging: an early short trial showed only a modest weight advantage over placebo, and a larger 24-week Phase 2b study in 536 subjects failed its primary endpoint, leading the programme to be abandoned. If the engineered, more stable version could not clear a pivotal human trial, there is no basis to assume the cruder parent would perform better.

Other research threads

Beyond fat loss, the fragment has surfaced in unrelated exploratory work, including in-silico and cell studies examining whether it influences the anticancer activity of doxorubicin in MCF-7 breast cancer cells. This is far upstream laboratory work with no clinical bearing, but it illustrates that the sequence draws scientific interest as a research tool rather than as a proven therapy.

Question	HGH Fragment 176-191	AOD-9604
Structure	Unmodified hGH tail (176-191)	Stabilised with added tyrosine and a disulfide bond
Human trials	None of its own	About six trials, around 900 participants
Blood sugar	Linked to a hyperglycaemic action	Reported neutral in trials
Outcome	Research-chemical market only	Development abandoned after Phase 2b

The bottom line: the fragment’s case is built on rodent studies and on borrowed human data from a related molecule that ultimately failed.

HGH Fragment 176-191 is not approved as a medicine anywhere and is treated as an unapproved drug or research material across major markets.

Jurisdiction	Status
United States	An unapproved drug that cannot be compounded. It was never among the peptides referred for advisory review, so it has no recent committee verdict attached.
United Kingdom	No marketing authorisation; sold only as research-grade material, with no lawful route for human supply.
Australia	Captured under the Poisons Standard scheduling that covers growth hormone fragments; prescription-only.
WADA (sport)	Explicitly named on the Prohibited List as a growth hormone fragment, banned at all times.

In the United States, HGH Fragment 176-191 is an unapproved drug and cannot be legally compounded. It was not among the peptides removed from Category 2 and referred for review, so unlike AOD-9604 it does not even have a recent advisory verdict attached to it, which leaves it in a quieter but no less restricted position. For the underlying rules, our explainer on the FDA category system sets out the distinction, and the US legal overview for peptides covers what that means in practice.

For sport, the distinction between the two molecules disappears. The WADA Prohibited List names growth hormone fragments directly, citing AOD-9604 and the 176-191 sequence together, so both are banned at all times. Our country guides break down peptide rules in the UK and Australia’s approach to peptides in more detail.

The bottom line: HGH Fragment 176-191 has no approved use anywhere and is explicitly banned in sport alongside its modified cousin.

The honest safety answer for the unmodified fragment is that it is largely uncharacterised in humans, because no dedicated human trial has studied it. The favourable safety headlines attached to this peptide come from a different molecule’s trials, and applying them to the parent assumes the two behave identically, which the hyperglycaemia signal in C-terminal fragments specifically calls into question. Of all the risks here, that blood-sugar uncertainty is the one most unique to this compound and the least acknowledged in the market.

On top of that mechanistic uncertainty sits a supply-chain problem. The fragment is sold as research-grade material with no pharmaceutical oversight, which introduces risks of contamination, mislabelling, and inaccurate peptide content. Independent verification is the only meaningful safeguard, which means checking a supplier’s certificate of analysis and weighing the vendor’s track record before trusting anything sold this way.

The bottom line: the fragment’s human safety is essentially unknown, and its blood-sugar effect may differ from the AOD-9604 data so often cited for it.

Is HGH Fragment 176-191 just a cheaper AOD-9604?

Not quite. It is the unmodified parent, while AOD-9604 adds a tyrosine and a disulfide bond for stability. They share a proposed mechanism, but the fragment lacks the stabilising changes and the clinical testing that the modified version received, so they are chemically and evidentially distinct.

Does HGH Fragment 176-191 raise blood sugar?

It might. Early work on synthetic C-terminal growth hormone fragments documented a hyperglycaemic action, and the unmodified sequence has been linked to insulin restriction. The “blood-sugar neutral” claim widely repeated for this peptide comes from the modified compound, not the parent.

Are there any human studies on the fragment itself?

No completed human efficacy trials exist for the unmodified sequence. Its evidence is rodent data plus borrowed results from AOD-9604, which is why no regulator treats it as a proven treatment.

Why is the fragment on the WADA banned list?

Because growth hormone fragments are treated as performance-relevant substances. WADA names the 176-191 sequence directly, alongside AOD-9604, so athletes face a sanction regardless of which version they use.

AOD-9604 is the stabilised, clinically-tested version of this fragment and the source of nearly all the human data attributed to it. The secretagogues CJC-1295 and ipamorelin take a different route to growth-hormone-related effects by prompting the body to release its own. 5-Amino-1MQ is another fat-loss compound circulating online, though it is a small molecule rather than a peptide. The GLP-1 medicines semaglutide and tirzepatide are the evidence-backed contrast, with the large human weight-loss trials that growth hormone fragments never produced. The broader landscape is mapped in our roundup of GLP-1 and fat-loss compounds.

There is no active drug-development programme for the unmodified fragment, and there is unlikely to be one. The more promising, stabilised version already failed its pivotal human trial, which removes the commercial incentive to revisit the cruder parent molecule. The fragment endures as a research-chemical product whose appeal depends heavily on being confused with AOD-9604 and on rodent results that have never been confirmed in people. The realistic outlook is continued grey-market availability rather than any path toward approval.

The bottom line: the fragment has no development pipeline, and its better-studied relative has already shown the approach does not deliver in humans.